Julie O'Neill

Insider · Director · ICLR

Julie O'Neill files insider transactions with the SEC as a director of Icon (ICLR). We hold 1 disclosed purchase or sale filed since 9 February 2015, 1 of them in the last 90 days.

Files forICLR
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure12 August 2026

Positions held

3 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 10 August 2026 — 11 August 2026Director · Icon (ICLR)7 Form 4 lines · source: SEC Form 4
Filed 17 April 2019 — 17 June 2024Director · HOOKIPA Pharma (HOOK)8 Form 4 lines · source: SEC Form 4
Filed 5 February 2015 — 28 February 2018EVP. Global Operations · Alexion Pharmaceuticals (ALXN)38 Form 4 lines · source: SEC Form 4

Everything they disclosed

53 entries, newest first — one per disclosure report, one per Form 4 line

exercised options over 1,732 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 10 August 2026 · filed 12 August 2026
▼ sold on the open market 95 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 105 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 642 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 73 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
exercised options over 1,732 shares of Icon (a derivative holding)SEC Form 412 August 2026Restricted Share Units · traded 10 August 2026 · filed 12 August 2026
was granted 1,324 shares of Icon (a derivative holding)SEC Form 412 August 2026Restricted Share Units · traded 10 August 2026 · filed 12 August 2026
was granted 49,000 shares of HOOKIPA Pharma (a derivative holding)SEC Form 418 June 2024Stock Option (Right to Buy) · traded 17 June 2024 · filed 18 June 2024
was granted 26,000 shares of HOOKIPA Pharma (a derivative holding)SEC Form 49 June 2023Stock Option (Right to Buy) · traded 9 June 2023 · filed 9 June 2023
was granted 20,000 shares of HOOKIPA Pharma (a derivative holding)SEC Form 41 July 2022Stock Option (Right to Buy) · traded 30 June 2022 · filed 1 July 2022
was granted 9,600 shares of HOOKIPA Pharma (a derivative holding)SEC Form 44 June 2021Stock Option (Right to Buy) · traded 1 June 2021 · filed 4 June 2021
was granted 4,969 shares of HOOKIPA PharmaSEC Form 423 October 2020Common Stock · traded 21 October 2020 · filed 23 October 2020
was granted 9,600 shares of HOOKIPA Pharma (a derivative holding)SEC Form 419 June 2020Stock Option (Right to Buy) · traded 18 June 2020 · filed 19 June 2020
was granted 9,600 shares of HOOKIPA Pharma (a derivative holding)SEC Form 43 January 2020Stock Option (Right to Buy) · traded 18 December 2019 · filed 3 January 2020
was granted 6,924 shares of HOOKIPA Pharma (a derivative holding)SEC Form 424 April 2019Stock Option (Right to Buy) · traded 17 April 2019 · filed 24 April 2019
was granted 8,940 shares of Alexion PharmaceuticalsSEC Form 42 March 2018Common Stock, par value $.0001 per share · traded 28 February 2018 · filed 2 March 2018
▼ sold on the open market 939 shares of Alexion PharmaceuticalsSEC Form 41 March 2018Common Stock, par value $.0001 per share · traded 27 February 2018 · filed 1 March 2018
▼ sold on the open market 686 shares of Alexion PharmaceuticalsSEC Form 41 March 2018Common Stock, par value $.0001 per share · traded 28 February 2018 · filed 1 March 2018
was granted 21,489 shares of Alexion PharmaceuticalsSEC Form 48 February 2018Common Stock, par value $.0001 per share · traded 6 February 2018 · filed 8 February 2018
was granted 7,500 shares of Alexion PharmaceuticalsSEC Form 48 February 2018Common Stock, par value $.0001 per share · traded 6 February 2018 · filed 8 February 2018
▼ sold on the open market 4,787 shares of Alexion PharmaceuticalsSEC Form 48 February 2018Common Stock, par value $.0001 per share · traded 8 February 2018 · filed 8 February 2018
▼ sold on the open market 2,119 shares of Alexion PharmaceuticalsSEC Form 47 February 2018Common Stock, par value $.0001 per share · traded 5 February 2018 · filed 7 February 2018
▼ sold on the open market 612 shares of Alexion PharmaceuticalsSEC Form 45 September 2017Common Stock, par value $.0001 per share · traded 31 August 2017 · filed 5 September 2017
▼ sold on the open market 1,841 shares of Alexion PharmaceuticalsSEC Form 45 September 2017Common Stock, par value $.0001 per share · traded 5 September 2017 · filed 5 September 2017
▼ sold on the open market 672 shares of Alexion PharmaceuticalsSEC Form 45 September 2017Common Stock, par value $.0001 per share · traded 5 September 2017 · filed 5 September 2017
▼ sold on the open market 600 shares of Alexion PharmaceuticalsSEC Form 45 September 2017Common Stock, par value $.0001 per share · traded 5 September 2017 · filed 5 September 2017
▼ sold on the open market 650 shares of Alexion PharmaceuticalsSEC Form 45 September 2017Common Stock, par value $.0001 per share · traded 5 September 2017 · filed 5 September 2017
▼ sold on the open market 11,160 shares of Alexion PharmaceuticalsSEC Form 430 August 2017Common Stock, par value $.0001 per share · traded 28 August 2017 · filed 30 August 2017
▼ sold on the open market 651 shares of Alexion PharmaceuticalsSEC Form 46 March 2017Common Stock, par value $.0001 per share · traded 2 March 2017 · filed 6 March 2017
▼ sold on the open market 910 shares of Alexion PharmaceuticalsSEC Form 41 March 2017Common Stock, par value $.0001 per share · traded 27 February 2017 · filed 1 March 2017
▼ sold on the open market 664 shares of Alexion PharmaceuticalsSEC Form 41 March 2017Common Stock, par value $.0001 per share · traded 28 February 2017 · filed 1 March 2017
was granted 7,500 shares of Alexion PharmaceuticalsSEC Form 41 March 2017Common Stock, par value $.0001 per share · traded 28 February 2017 · filed 1 March 2017
was granted 14,800 shares of Alexion Pharmaceuticals (a derivative holding)SEC Form 41 March 2017Option to Purchase Common Stock · traded 28 February 2017 · filed 1 March 2017
▼ sold on the open market 2,795 shares of Alexion PharmaceuticalsSEC Form 48 February 2017Common Stock, par value $.0001 per share · traded 6 February 2017 · filed 8 February 2017
▼ sold on the open market 650 shares of Alexion PharmaceuticalsSEC Form 42 September 2016Common Stock, par value $.0001 per share · traded 2 September 2016 · filed 2 September 2016
▼ sold on the open market 651 shares of Alexion PharmaceuticalsSEC Form 44 March 2016Common Stock, par value $.0001 per share · traded 2 March 2016 · filed 4 March 2016
was granted 7,000 shares of Alexion PharmaceuticalsSEC Form 41 March 2016Common Stock, par value $.0001 per share · traded 26 February 2016 · filed 1 March 2016
▼ sold on the open market 663 shares of Alexion PharmaceuticalsSEC Form 41 March 2016Common Stock, par value $.0001 per share · traded 29 February 2016 · filed 1 March 2016
was granted 31,000 shares of Alexion Pharmaceuticals (a derivative holding)SEC Form 41 March 2016Option to Purchase Common Stock · traded 26 February 2016 · filed 1 March 2016
was granted 11,763 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 4 February 2016 · filed 8 February 2016
▼ sold on the open market 348 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 352 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 351 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 499 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 530 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 5 February 2016 · filed 8 February 2016
▼ sold on the open market 23 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 8 February 2016 · filed 8 February 2016
▼ sold on the open market 755 shares of Alexion PharmaceuticalsSEC Form 48 February 2016Common Stock, par value $.0001 per share · traded 8 February 2016 · filed 8 February 2016
▼ sold on the open market 647 shares of Alexion PharmaceuticalsSEC Form 410 September 2015Common Stock, par value $.0001 per share · traded 2 September 2015 · filed 10 September 2015
▼ sold on the open market 5,100 shares of Alexion PharmaceuticalsSEC Form 43 March 2015Common Stock, par value $.0001 per share · traded 27 February 2015 · filed 3 March 2015
▼ sold on the open market 6,565 shares of Alexion PharmaceuticalsSEC Form 43 March 2015Common Stock, par value $.0001 per share · traded 2 March 2015 · filed 3 March 2015
was granted 24,400 shares of Alexion Pharmaceuticals (a derivative holding)SEC Form 43 March 2015Option to Purchase Common Stock · traded 27 February 2015 · filed 3 March 2015
▼ sold on the open market 795 shares of Alexion PharmaceuticalsSEC Form 412 February 2015Common Stock, par value $.0001 per share · traded 10 February 2015 · filed 12 February 2015
was granted 4,350 shares of Alexion PharmaceuticalsSEC Form 49 February 2015Common Stock, par value $.0001 per share · traded 5 February 2015 · filed 9 February 2015

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.